Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Acquisition to Strengthen Transplant and Oncology Businesses CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq:...
CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq: ANOR; TSX: AOM) announced today the expiration of the waiting...
AnorMED Board Recommends Shareholders Accept Genzyme Offer LANGLEY, BC, Nov. 3 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (NASDAQ:ANOR; TSX:AOM) today released its...
SEATTLE, Oct. 26 /PRNewswire/ -- Koronis Pharmaceuticals, Inc. today announced the appointment of Stephen Becker, M.D., as chief medical officer. Dr. Becker joins Koronis from AnorMED...
VANCOUVER, Oct. 23 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that it has completed enrollment in the second pivotal Phase III clinical trial evaluating its...
Genzyme to Gain Late-Stage Transplantation Product Candidate VANCOUVER, BC, and CAMBRIDGE, MA, Oct. 17 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq: ANOR;...
Millennium has the right to match Genzyme's 'superior proposal' VANCOUVER, Oct. 11 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or "the Company") (NASDAQ:ANOR; TSX:AOM) announced that it...
Millennium has the right to match Genzyme's 'superior proposal' VANCOUVER, Oct. 11 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or "the Company") (NASDAQ:ANOR; TSX:AOM) announced that it...
VANCOUVER, Oct. 10 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) announced today that it has received a proposal from Genzyme Corporation (NASDAQ:GENZ), acting through its wholly...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
